Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine

Overview

About this study

The purpose of this study is to evaluate approximately 15,000 health care workers at risk for being exposed to COVID-19. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Completed Informed Consent.
  • Age ≥ 18 years old.
  • Individual is currently working with a trial participating site where individuals receive healthcare ("healthcare worker") or is associated with the site through emergency services or related healthcare services.
  • Able to speak and read English or Spanish.
  • At risk for COVID-19 infection through one or more of the following work exposures:
    • in the Intensive care unit; or
    • in the Emergency department; or
    • in Emergency services; or
    • in a COVID-19 hospital unit/ward; or
    • in respiratory services; or
    • in COVID-19 testing location;
    • in inpatient hospital unit/area with potential COVID-19 cases.

Exclusion Criteria:

  • Prior diagnosis of COVID-19 infection.
  • Participation in another COVID-19 prophylaxis trial within 30 days of consent.
  • Respiratory illness with new-onset fever (Temperature > 100°F) or ongoing cough or dyspnea within 14 days.
  • Known allergy to HCQ or chloroquine.
  • Congenital prolonged QT syndrome.
  • Current or planned use of QT prolonging drugs (e.g., procainamide, disopyramide, mexiletine, flecainide, propafenone, amiodarone, sotalol, cimetidine, dronedarone, dofetilide, levofloxacin, ciprofloxacin, moxifloxacin).
  • End stage renal disease.
  • Pre-existing retinopathy.
  • Current or planned use of the following for treatment or prevention of COVID-19 infection:
    • Hydroxychloroquine (study drug) or chloroquine;
    • Azithromycin.
  • Known cirrhosis or severe liver disease.
  • History of severe skin reactions such as Steven-Johnson syndrome, toxic epidermal necrolysis.
  • History of psoriasis or porphyria.
  • Ventricular arrhythmias requiring medical treatment.
  • Severe coronary artery disease or heart failure/cardiomyopathy with ongoing symptoms.
  • Current or planned use of use of anti-seizure drugs.
  • History of Glucose-6-phosphate dehydrogenase deficiency.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mohammad Murad, M.D.

Open for enrollment

Contact information:

Department of Medicine - Clinical Trials Unit

(507) 266-1944

RSTDOMCTU@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20486315

Mayo Clinic Footer